Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–82.
2. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703.
3. Pathak A, Purkayastha A, Gupta A, Guleria B, Rathore A. High Dose methotrexate in oncological practice: A review and update on recent trends in administration and management of toxicity. Acta Sci Cancer Biol. 2018;2:27–30.
4. Rouch JA, Burton B, Dabb A, Brown V, Seung AH, Kinsman K, et al. Comparison of enteral and parenteral methods of urine alkalinization in patients receiving high-dose methotrexate. J Oncol Pharm Pract. 2017;23(1):3–9.
5. Cohen B, Laish I, Brosh-Nissimov T, Hoffman A, Katz LH, Braunstein R, et al. Efficacy of urine alkalinization by oral administration of sodium bicarbonate: a prospective open-label trial. Am J Emerg Med. 2013;31(12):1703–6.